{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.88","upperLimit":"1.69","value":"1.2"},{"groupId":"OG001","lowerLimit":"0.49","upperLimit":"2.14","value":"1.0"}]}],"title":"Pre-vaccination"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.72","upperLimit":"5.74","value":"4.0"},{"groupId":"OG001","lowerLimit":"2.25","upperLimit":"12.00","value":"5.2"}]}],"title":"4 weeks post-vaccination"}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"description":"Anti-tetanus antibody was measured in serum samples immediately prior to and 4 weeks after administration of a tetanus toxoid adsorbed booster vaccine. The tetanus antibody test was an ELISA that used tetanus toxoid as a capturing reagent and alkaline phosphatase-conjugated anti-human IgG (γ) for detection.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received 2 intravenous infusions of rituximab 1000 mg, 14 days apart + methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.","id":"OG000","title":"Rituximab + Methotrexate (Group A)"},{"description":"Patients received methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.","id":"OG001","title":"Methotrexate (Group B)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Immune response per-protocol population: Group A - All patients randomized to Group A who received any rituximab infusion and any vaccine and had pre-vaccination and 4-week post-vaccination blood samples. Group B - All patients randomized to Group B who received any vaccine and had pre-vaccination and 4-week post-vaccination blood samples.","reportingStatus":"POSTED","timeFrame":"Week 24 to Week 28 for Group A and Day 1 to Week 4 for Group B","title":"Serum Level of Anti-tetanus Antibody Measured Immediately Prior to and 4 Weeks After Administration of a Tetanus Toxoid Adsorbed Booster Vaccine","type":"SECONDARY","unitOfMeasure":"IU/mL"}